Chardan Capital: Krystal Biotech (KRYS) has $35 Target Has New Rating.

June 29, 2018 - By Rebecca Betts

What Price Target Has Chardan Capital Given Krystal Biotech (KRYS)

Analysts at Chardan Capital gave “Buy” rating and has price target of $35 on KRYS’s shares. On Thursday, 28 June a coverage started with Krystal Biotech (KRYS)‘s stock.

KRYS hit $14.79 during the last trading session after $0.37 change.Currently Krystal Biotech, Inc. is after 0.00% change in last June 29, 2017. KRYS has 5,264 shares volume. KRYS underperformed by 12.57% the S&P500.

Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States.The company has $152.48 million market cap. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.Last it reported negative earnings. It also engages in developing KB105, which is in preclinical studies to treat Lamellar Ichthyosis, which is an autosomal recessive disorder.

Another two news for Krystal Biotech, Inc. (NASDAQ:KRYS) were briefly announced by: Streetinsider.com on June 28, 2018 with title “Chardan Capital Markets Starts Krystal Biotech (KRYS) at Buy”. The other Benzinga.com‘s article was titled “40 Biggest Movers From Yesterday” and announced on June 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: